CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishThe present invention relates to an antibody capable of binding with highaffinity and high selectivity to the ectodomain of the transmembrane proteoglycan (PG) NG2/CSPG4. The invention specifically refers to said antibody possessing the ability to uniquely induce programmed cell death through canonical caspase-dependent apoptosis or authophagy, 5 in cancer cells specifically expressing such protein, and without the participation of other exogenously added factors. Moreover, the present invention refers to a composition comprising the antibody of the invention as pharmaceutical excipients.
Pro-apoptotic anti-NG2/CSPG4 antibodies and their uses in disease therapy / Perris, R; Dallatomasina, A; Tamburini, E; NicolosiPA, ; Mucignat, Mt. - ELETTRONICO. - (2016).
| Titolo: | Pro-apoptotic anti-NG2/CSPG4 antibodies and their uses in disease therapy | |
| Autori: | ||
| Data di pubblicazione: | 2016 | |
| Citazione: | Pro-apoptotic anti-NG2/CSPG4 antibodies and their uses in disease therapy / Perris, R; Dallatomasina, A; Tamburini, E; NicolosiPA, ; Mucignat, Mt. - ELETTRONICO. - (2016). | |
| Abstract: | The present invention relates to an antibody capable of binding with highaffinity and high selectivity to the ectodomain of the transmembrane proteoglycan (PG) NG2/CSPG4. The invention specifically refers to said antibody possessing the ability to uniquely induce programmed cell death through canonical caspase-dependent apoptosis or authophagy, 5 in cancer cells specifically expressing such protein, and without the participation of other exogenously added factors. Moreover, the present invention refers to a composition comprising the antibody of the invention as pharmaceutical excipients. | |
| Handle: | http://hdl.handle.net/11381/2891268 | |
| Appare nelle tipologie: | 5.1 Brevetto concesso |
File in questo prodotto:
Copyright © 2021